8-K: Neurocrine Biosciences Reports Strong Q2 2025 Sales, Narrows INGREZZA Guidance Amidst Pipeline Progress

Neurocrine Biosciences announced robust second-quarter 2025 financial results, driven by strong INGREZZA and CRENESSITY sales, while narrowing its full-year INGREZZA sales guidance.

Summary

• Total Net Product Sales reached $682 million for the second quarter ended June 30, 2025, representing 17% year-over-year growth.
• INGREZZA net product sales for Q2 2025 were $624 million, showing 15% sequential growth over Q1 2025 and 8% growth year-over-year, driven by strong patient demand and a new quarterly record in new prescriptions.
• CRENESSITY net product sales for Q2 2025 were $53 million, with 664 total new patient enrollment start forms and 76% reimbursement coverage for dispensed scripts.
• Full-year 2025 INGREZZA net product sales guidance was narrowed from $2.5 $2.6 billion to $2.5 $2.55 billion, reflecting double-digit volume growth partially offset by lower net price due to expanded access.
• GAAP Net Income for Q2 2025 was $107.5 million ($1.06 diluted EPS), compared to $65.0 million ($0.63 diluted EPS) for Q2 2024.
• Non-GAAP Net Income for Q2 2025 was $166.2 million ($1.65 diluted EPS), compared to $168.9 million ($1.63 diluted EPS) for Q2 2024.
• The company's cash, cash equivalents, and marketable securities totaled approximately $1.8 billion as of June 30, 2025.
• A Phase 3 study of valbenazine for the adjunctive treatment of schizophrenia did not meet its primary endpoint, though consistent trends favoring valbenazine were observed.
• Neurocrine initiated a Phase 3 registrational program for NBI-568 in schizophrenia and a Phase 1 study of NBIP-1435 for congenital adrenal hyperplasia.

Sentiment

Score: 7

Explanation: The filing indicates strong commercial performance for key products, significant year-over-year GAAP financial improvements, and active pipeline advancement. While there is a slight narrowing of INGREZZA guidance and a clinical trial failure, these are minor setbacks that do not overshadow the overall positive trajectory and strong balance sheet, suggesting a generally positive outlook.

Positives

• Total Net Product Sales increased 17% year-over-year to $682 million in Q2 2025.
• INGREZZA net product sales grew 15% sequentially and 8% year-over-year to $624 million, driven by strong patient demand and a new quarterly record in new prescriptions.
• Expanded formulary access for INGREZZA now covers approximately 70% of tardive dyskinesia and Huntington's disease Medicare beneficiaries.
• CRENESSITY's early launch shows robust demand with $53 million in net product sales and 664 new patient enrollment start forms in Q2 2025, achieving 76% reimbursement coverage.
• GAAP Net Income significantly increased to $107.5 million in Q2 2025 from $65.0 million in Q2 2024.
• Diluted GAAP EPS increased to $1.06 in Q2 2025 from $0.63 in Q2 2024.
• Non-GAAP Diluted EPS increased to $1.65 in Q2 2025 from $1.63 in Q2 2024.
• Strong balance sheet with approximately $1.8 billion in cash, cash equivalents, and marketable securities as of June 30, 2025.
• Initiated Phase 3 registrational program for NBI-568, an oral muscarinic M4 selective orthosteric agonist, as a potential treatment for adults with schizophrenia.
• Presented one-year data showing sustained efficacy of CRENESSITY in Adult Patients and improvements in weight-related effects of glucocorticoid treatment at ENDO 2025.
• Initiated the Phase 1 study of NBIP-1435, a long-acting corticotropin-releasing factor type 1 (CRF-1) receptor antagonist, for the potential treatment of congenital adrenal hyperplasia.
• Repurchased $168 million of common stock as of June 30, 2025, with $332 million remaining under the authorized program.

Negatives

• INGREZZA 2025 net product sales guidance was narrowed from $2.5 $2.6 billion to $2.5 $2.55 billion, reflecting lower net price due to expanded access, partially offsetting volume growth.
• The Phase 3 study of valbenazine for the adjunctive treatment of schizophrenia did not meet its primary endpoint.
• Non-GAAP Net Income decreased slightly to $166.2 million in Q2 2025 from $168.9 million in Q2 2024.
• Increased GAAP Research and Development (R&D) expense to $244.3 million in Q2 2025 from $191.1 million in Q2 2024, driven by portfolio expansion and a $15 million development milestone.
• Increased GAAP Selling, General, and Administrative (SG&A) expense to $286.3 million in Q2 2025 from $242.0 million in Q2 2024, due to incremental investment in CRENESSITY launch activities and INGREZZA sales team expansion.
• Incurred an unrealized loss on equity investments of $6.7 million in Q2 2025.

Risks

• Risks and uncertainties associated with Neurocrine Biosciences' business and finances in general.
• Risks and uncertainties associated with the commercialization of INGREZZA and CRENESSITY.
• Risks related to the development of product candidates.
• Risks associated with dependence on third parties for development, manufacturing, and commercialization activities for products and product candidates, and the ability to manage these third parties.
• Risks that the FDA or other regulatory authorities may make adverse decisions regarding products or product candidates.
• Risks that development activities may not be initiated or completed on time or at all, or may be delayed for regulatory, manufacturing, or other reasons.
• Risks that development activities may not be successful or replicate previous clinical trial results, may fail to demonstrate that product candidates are safe and effective, or may not be predictive of real-world results or of results in subsequent clinical trials.
• Risks that the potential benefits of agreements with collaboration partners may never be realized.
• Risks that products and/or product candidates may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse.
• Risks associated with government and third-party regulatory and/or policy efforts which may, among other things, impose sales and pharmaceutical pricing controls on products or limit coverage and/or reimbursement for products.
• Risks associated with competition from other therapies or products, including potential generic entrants for products.

Future Outlook

Neurocrine Biosciences is transitioning into a new chapter of growth and diversification, aiming to advance and expand its neuropsychiatry pipeline, including ongoing registrational programs for osavampator in major depressive disorder and NBI-568 in schizophrenia. The company expects continued double-digit volume growth for INGREZZA, partially offset by lower net price due to expanded access, and anticipates robust demand for CRENESSITY.

Management Comments

• "As we begin our transition into a new chapter of growth and diversification for Neurocrine, we're pleased with our second quarter commercial performance across tardive dyskinesia, Huntington's chorea, and now, classic congenital adrenal hyperplasia." Kyle W. Gano, Ph.D., Chief Executive Officer.
• "Although still early in our launch, the demand for CRENESSITY remains robust, underscoring the significant unmet need for a novel treatment option for patients with CAH." Kyle W. Gano, Ph.D., Chief Executive Officer.
• "With revenue contributions from both INGREZZA and CRENESSITY along with our strong balance sheet, we are well-positioned to advance and expand our neuropsychiatry pipeline, including our ongoing registrational programs in major depressive disorder with osavampator and in schizophrenia with NBI-568, our selective M4 muscarinic agonist." Kyle W. Gano, Ph.D., Chief Executive Officer.

Industry Context

Neurocrine Biosciences operates in the highly competitive biopharmaceutical sector, specializing in neuropsychiatric, neurological, and neuroendocrine disorders. The continued strong performance of INGREZZA reinforces its market position in tardive dyskinesia and Huntington's chorea. The successful early launch of CRENESSITY addresses a significant unmet need in classic congenital adrenal hyperplasia, demonstrating the company's ability to bring new treatments to market. Strategic pipeline advancements, particularly in schizophrenia and major depressive disorder, align with broader industry trends focusing on complex neurological conditions. While the Phase 3 study failure for valbenazine in schizophrenia highlights inherent drug development risks, the company's commitment to next-generation VMAT2 inhibitors shows adaptability and a long-term vision for its therapeutic areas.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark against industry standards.

Stakeholder Impact

• Shareholders: Positive impact due to strong sales growth, increased GAAP net income and EPS, an active share repurchase program, and pipeline advancements, potentially leading to increased shareholder value.
• Patients: Positive impact through continued access to INGREZZA for tardive dyskinesia and Huntington's chorea, and the successful launch of CRENESSITY providing a novel treatment option for classic congenital adrenal hyperplasia. Future potential treatments from the pipeline could also benefit patients.
• Employees: Continued investment in sales teams and R&D suggests stable to growing employment opportunities.
• Creditors: Strong cash position and financial performance indicate low credit risk.

Next Steps

• Advance and expand the neuropsychiatry pipeline, including ongoing registrational programs for osavampator in major depressive disorder and NBI-568 in schizophrenia.
• Publish full results of the Phase 3 study of valbenazine for the adjunctive treatment of schizophrenia at a later date.
• Utilize insights from the valbenazine schizophrenia study to inform the development of next-generation vesicular monoamine transporter 2 (VMAT2) inhibitors.
• Host an R&D Day in San Diego on December 16, 2025.

Key Dates

Recommendation

While Neurocrine Biosciences demonstrates strong commercial execution with INGREZZA and a promising early launch for CRENESSITY, the slight narrowing of INGREZZA guidance and the failure of a Phase 3 schizophrenia study for valbenazine introduce some caution. The robust pipeline and strong cash position provide a solid foundation, but the mixed clinical news and guidance adjustment suggest a 'hold' position until further clarity on pipeline success and sustained growth rates.

Keywords

Neurocrine Biosciences, NBIX, Pharmaceuticals, Biotechnology, Neuroscience, Tardive Dyskinesia, Huntington's Chorea, Congenital Adrenal Hyperplasia, Schizophrenia, Major Depressive Disorder, INGREZZA, CRENESSITY, Clinical Trials, Drug Development, Financial Results, Earnings